Appendix B - Common Laboratory Tests

Acid phosphatase

 Male

2–12 U/L

16.7

33–200 nkat/L

 Female

0.3–9.2 U/L

16.7

5–154 nkat/L

Activated partial thromboplastin time (aPTT)

25–40 seconds

Adrenocorticotropic hormone (ACTH)

15–80 pg/mL or ng/L

0.2202

3.3–17.6 pmol/L

Alanine aminotransferase (ALT, SGPT)

7–53 U/L

0.01667

0.12–0.88 μkat/L

Albumin

3.5–5.0 g/dL

10

35–50 g/L

Albumin:creatinine ratio (urine)

0.113

 Normal

< 30 mg/g creatinine

< 3.4 mg/mmol creatinine

  Microalbuminuria

30–300 mg/g creatinine

3.4–34 mg/mmol creatinine

  Proteinuria

> 300 mg/g creatinine

> 34 mg/mmol creatinine

 or

or

 Normal

  Male

< 18 mg/g creatinine

0.113

< 2.0 mg/mmol creatinine

  Female

< 25 mg/g creatinine

0.113

< 2.8 mg/mmol creatinine

 Microalbuminuria

  Male

18–180 mg/g creatinine

0.113

2.0–20 mg/mmol creatinine

  Female

25–250 mg/g creatinine

0.113

2.8–28 mg/mmol creatinine

 Proteinuria

  Male

> 180 mg/g creatinine

0.113

> 20 mg/mmol creatinine

  Female

> 250 mg/mmol creatinine

0.113

> 28 mg/mmol creatinine

Alcohol

 See under Ethanol

Aldosterone

 Supine

< 16 ng/dL

27.7

< 444 pmol/L

 Upright

< 31 ng/dL

27.7

< 860 pmol/L

Alkaline phosphatase

 10–15 years

130–550 IU/L

0.01667

2.17–9.17 μkat/L

 16–20 years

70–260 IU/L

0.01667

1.17–4.33 μkat/L

 > 20 years

38–126 IU/L

0.01667

0.63–2.10 μkat/L

α-Fetoprotein (AFP)

< 15 ng/mL

1

< 15 mcg/L

α-1-Antitrypsin

80–200 mg/dL

0.01

0.8–2.0 g/L

Amikacin, therapeutic

 Peak

15–30 mg/L

1.71

25.6–51.3 μmol/L

 Trough

≤ 8 mg/L

1.71

≤ 13.7 μmol/L

Amitriptyline

80–200 ng/mL or mcg/L

3.605

288–721 nmol/L

Ammonia (plasma)

15–56 mcg NH₃/dL

0.5872

9–33 μmol NH₃/L

Amylase

25–115 U/L

0.01667

0.42–1.92 μkat/L

Androstenedione

50–250 ng/dL

0.0349

1.7–8.7 nmol/L

Angiotensin-converting enzyme

15–70 units/L

16.67

250–1167 nkat/L

Anion gap

7–16 mEq/L

1

7–16 mmol/L

Anti–double-stranded DNA (anti-ds DNA)

Negative

Anti-HAV

Negative

Anti-HBc

Negative

Anti-HBs

Negative

Anti-HCV

Negative

Anti-Sm antibody

Negative

Antinuclear antibody (ANA)

Negative

Apolipoprotein A-1

 Male

95–175 mg/dL

0.01

0.95–1.75 g/L

 Female

100–200 mg/dL

0.01

1.0–2.0 g/L

Apolipoprotein B

 Male

50–110 mg/dL

0.01

0.5–1.10 g/L

 Female

50–105 mg/dL

0.01

0.5–1.05 g/L

Aspartate aminotransferase (AST, SGOT)

11–47 IU/L

0.01667

0.18–0.78 μkat/L

β₂-Microglobulin

< 0.2 mg/dL

10

< 2 mg/L

Bicarbonate

22–26 mEq/L

1

22–26 mmol/L

Bilirubin

 Total

0.3–1.1 mg/dL

17.1

5.1–18.8 μmol/L

 Direct

0–0.3 mg/dL

17.1

0–5.1 μmol/L

 Indirect

0.1–1.0 mg/dL

17.1

1.7–17.1 μmol/L

Bleeding time

3–7 minutes

60

180–420 seconds

Blood gases (arterial)

 pH

7.35–7.45

1

7.35–7.45

 PO₂

80–105 mm Hg

0.133

10.6–14.0 kPa

 PCO₂

35–45 mm Hg

0.133

4.7–6.0 kPa

 HCO₃

22–26 mEq/L

1

22–26 mmol/L

 O₂ saturation

≥ 95%

0.01

≥ 0.95

Blood urea nitrogen (BUN)

8–25 mg/dL

0.357

2.9–8.9 mmol/L

B-type natriuretic peptide (BNP)

0–99 pg/mL

1

0.289

0–99 ng/L

0–29 pmol/L

B-type natriuretic peptide, N-terminal fragment (NT-proBNP)

0–299 pg/mL

1

0.118

0–299 ng/L

0-35 pmol/L

BUN-to-creatinine ratio

10:1–20:1

40:1-100:1

C-peptide

0.51–2.70 ng/mL

331

0.331

170–894 pmol/L

0.17–0.89 nmol/L

C-reactive protein

< 0.8 mg/dL

10

< 8 mg/L

CA-125

< 35 units/mL

1

< 35 kU/L

CA 15–3

< 30 units/mL

1

< 30 kU/L

CA 19–9

< 37 units/mL

1

< 37 kU/L

CA 27.29

< 38 units/mL

1

< 38 kU/L

Calcium

 Total

8.6–10.3 mg/dL

0.25

2.15–2.58 mmol/L

4.3–5.16 mEq/L

0.50

2.15–2.58 mmol/L

 Ionized

4.5–5.1 mg/dL

0.25

1.13–1.28 mmol/L

2.26–2.56 mEq/L

0.50

1.13–1.28 mmol/L

Carbamazepine, therapeutic

4–12 mg/L

4.23

17–51 μmol/L

Carboxyhemoglobin (nonsmoker)

< 2%

0.01

< 0.02

Carcinoembryonic antigen (CEA)

 Nonsmokers

< 2.5 ng/mL

1

< 2.5 mcg/L

 Smokers

< 5 ng/mL

1

< 5 mcg/L

CD4 lymphocyte count

31%–61% of total lymphocytes

0.01

0.31–0.61 of total lymphocytes

CD8 lymphocyte count

18%–39% of total lymphocytes

0.01

0.18–0.39 of total lymphocytes

Cerebrospinal fluid (CSF)

 Pressure

75–175 mm H₂O

0.0098

 0.74-1.72 kPa

 Glucose

40–70 mg/dL

0.0555

2.2–3.9 mmol/L

 Protein

15–45 mg/dL

0.01

0.15–0.45 g/L

 White blood cell (WBC) count

< 10/mm³

1

< 10 × 10⁶/L

Ceruloplasmin

18–45 mg/dL

10

180–450 mg/L

Chloride

97–110 mEq/L

1

97–110 mmol/L

Cholesterol

 Desirable

< 200 mg/dL

0.0259

< 5.18 mmol/L

 Borderline high

200–239 mg/dL

0.0259

5.18–6.19 mmol/L

 High

≥ 240 mg/dL

0.0259

≥6.2 mmol/L

Chorionic gonadotropin (β-hCG)

Clozapine, minimum trough

< 5 mIU/mL

300–350 ng/mL or mcg/L

1

3.06

0.00306

< 5 IU/L

918–1,071 nmol/L

0.92–1.07 μmol/L

CO₂ content

22–30 mEq/L

1

22–30 mmol/L

Complement component 3 (C3)

70–160 mg/dL

0.01

0.70–1.60 g/L

Complement component 4 (C4)

20–40 mg/dL

0.01

0.20–0.40 g/L

Copper

70–150 mcg/dL

0.157

11–24 μmol/L

Cortisol (fasting, morning)

5–25 mcg/dL

27.6

138–690 nmol/L

Creatine kinase

 Male

30–200 IU/L

0.01667

0.50–3.33 μkat/L

 Female

20–170 IU/L

0.01667

0.33–2.83 μkat/L

 MB fraction

0–7 IU/L

0.01667

0.0–0.12 μkat/L

Creatinine clearance (CrCl)

85–135 mL/min/1.73 m²

0.00963

0.01667

0.82–1.30 mL/s/m²

85–135 mL/s/1.73 m²

Creatinine

 Male 4–20 years

0.2–1.0 mg/dL

88.4

18–88 μmol/L

 Female 4–20 years

0.2–1.0 mg/dL

88.4

18–88 μmol/L

 Male (adults)

0.7–1.3 mg/dL

88.4

62–115 μmol/L

 Female (adults)

0.6–1.1 mg/dL

88.4

53–97 μmol/L

Cyclosporine

 Renal, cardiac, liver, or pancreatic transplant

100–400 ng/mL or mcg/L

0.832

83–333 nmol/L

Cryptococcal antigen

Negative

D-dimers

< 250 ng/mL

1

< 250 mcg/L

Desipramine

75–300 ng/mL or mcg/L

3.75

281–1125 nmol/L

Dexamethasone suppression test (DST) (overnight), 8:00 am cortisol

< 5 mcg/dL

27.6

< 138 nmol/L

DHEAS (dehydroepiandrosterone sulfate)

 Male

170–670 mcg/dL

0.0272

4.6–18.2 μmol/L

 Female

  Premenopausal

50–540 mcg/dL

0.0272

1.4–14.7 μmol/L

  Postmenopausal

30–260 mcg/dL

0.0272

0.8–7.1 μmol/L

Digoxin, therapeutic (heart failure)

0.5–0.8 ng/mL or mcg/L

1.28

0.6–1.0 nmol/L

 Therapeutic (atrial fibrillation)

0.8–2.0 ng/mL or mcg/L

1.28

1.0–2.6 nmol/L

Erythrocyte count (blood)

 See under red blood cell (RBC) count

Erythrocyte sedimentation rate (ESR)

 Westergren

  Male

0–20 mm/h

  Female

0–30 mm/h

 Wintrobe

  Male

0–9 mm/h

  Female

0–15 mm/h

Erythropoietin

2–25 mIU/mL

1

2–25 IU/L

Estradiol

  Male

10–36 pg/mL

3.67

37–132 pmol/L

  Female

34–170 pg/mL

3.67

125–624 pmol/L

Ethanol, legal intoxication (depends on location)

≥ 50–100 mg/dL

0.217

≥10.9–21.7 mmol/L

≥ 0.05–0.1%

217

≥10.9–21.7 mmol/L

Ethosuximide, therapeutic

40–100 mg/L or mcg/mL

7.08

283–708 μmol/L

Factor VIII or factor IX

 Severe hemophilia

< 1 IU/dL

0.01

< 0.01 IU/mL

 Moderate hemophilia

1–5 IU/dL

0.01

0.01–0.05 IU/mL

 Mild hemophilia

> 5 IU/dL

0.01

> 0.05 IU/mL

 Usual adult levels

60 to 140 IU/dL

0.01

0.60–1.40 IU/mL

Ferritin

 Male

20–250 ng/mL

1

2.25

20–250 mcg/L

45-562 pmol/L

 Female

10–150 ng/mL

1

2.25

10–150 mcg/L

22-337 pmol/L

Fibrin degradation products (FDP)

2–10 mg/L

Fibrinogen

200–400 mg/dL

0.01

2.0–4.0 g/L

Folate (plasma)

3.1–12.4 ng/mL

2.266

7.0–28.1 nmol/L

Folate (RBC)

125–600 ng/mL

2.266

283–1,360 nmol/L

Follicle-stimulating hormone (FSH)

 Male

1–7 mIU/mL

1

1–7 IU/L

 Female

  Follicular phase

1–9 mIU/mL

1

1–9 IU/L

  Midcycle

6–26 mIU/mL

1

6–26 IU/L

  Luteal phase

1–9 mIU/mL

1

1–9 IU/L

  Postmenopausal

30–118 mIU/mL

1

30–118 IU/L

Free thyroxine index (FT₄I)

6.5–12.5

Gamma glutamyltransferase (GGT)

0–30 U/L

0.01667

0–0.50 μkat/L

Gastrin (fasting)

0–130 pg/mL

1

0–130 ng/L

Gentamicin, therapeutic (traditional dosing)

 Peak

4–10 mg/L

2.09

8.4–21 μmol/L

 Trough

≤ 2 mg/L

2.09

≤ 4.2 μmol/L

Globulin

2.3–3.5 g/dL

10

23–35 g/L

Glucose (fasting, plasma)

65–109 mg/dL

0.0555

3.6–6.0 mmol/L

Glucose, 2-hour postprandial blood (PPBG)

< 140 mg/dL

0.0555

< 7.8 mmol/L

Granulocyte count

1.8–6.6 × 10³/mm³

10⁶

1.8–6.6 × 10⁹/L

Growth hormone (fasting)

 Male

< 5 ng/mL

1

< 5 mcg/L

 Female

< 10 ng/mL

1

< 10 mcg/L

Haptoglobin

60–270 mg/dL

0.01

0.6–2.7 g/L

Hepatitis B surface antigen, extracellular form (HBeAg)

Negative

Hepatitis B surface antigen (HbsAg)

Negative

Hepatitis B virus (HBV) DNA

Negative

Hematocrit

 Male

40.7%–50.3%

0.01

0.407–0.503

 Female

36.1%–44.3%

0.01

0.361–0.443

Hemoglobin (blood)

 Male

13.8–17.2 g/dL

10

138–172 g/L

0.621

8.56–10.68 mmol/L

 Female

12.1–15.1 g/dL

10

121–151 g/L

0.621

7.51–9.36 mmol/L

Hemoglobin A1c

4.0%–6.0%

0.01

^a

0.04–0.06

20–42 mmol/mol hemoglobin

Heparin

 Via protamine titration method

0.2–0.4 units/mL

 Via antifactor Xa assay

0.3–0.7 units/mL

High-density lipoprotein (HDL) cholesterol

> 35 mg/dL

0.0259

> 0.91 mmol/L

Homocysteine

3.3–10.4 μmol/L

Ibuprofen

 Therapeutic

10–50 mcg/mL

4.85

49–243 μmol/L

 Toxic

≥ 100 mcg/mL

4.85

≥ 485 μmol/L

Imipramine, therapeutic

100–300 ng/mL or mcg/L

3.57

357–1071 nmol/L

Immunoglobulin A (IgA)

85–385 mg/dL

0.01

0.85–3.85 g/L

Immunoglobulin G (IgG)

565–1765 mg/dL

0.01

5.65–17.65 g/L

Immunoglobulin M (IgM)

53–375 mg/dL

0.01

0.53–3.75 g/L

Insulin (fasting)

2–20 μU/mL or mU/L

7.175

14.35–143.5 pmol/L

International normalized ratio (INR), therapeutic

2.0–3.0 (2.5–3.5 for some indications)

Iron

 Male

45–160 mcg/dL

0.179

8.1–28.6 μmol/L

 Female

30–160 mcg/dL

0.179

5.4–28.6 μmol/L

Iron-binding capacity (total)

220–420 mcg/dL

0.179

39.4–75.2 μmol/L

Iron saturation

15%–50%

0.01

0.15–0.50

Itraconazole

 Trough, therapeutic

0.5–1 mcg/mL or mg/L

1.42

0.7-1.4 μmol/L

Lactate (plasma)

0.7–2.1 mEq/L

6.3–18.9 mg/dL

1

0.111

0.7–2.1 mmol/L

0.7–2.1 mmol/L

Lactate dehydrogenase (LDH)

100–250 IU/L

0.01667

1.67–4.17 μkat/L

Lead

< 25 mcg/dL

0.0483

< 1.21 μmol/L

Leukocyte count

3.8–9.8 × 10³/mm³

10⁶

3.8–9.8 × 10⁹/L

Lidocaine, therapeutic

1.5–6.0 mcg/mL or mg/L

4.27

6.4–25.6 μmol/L

Lipase

< 100 IU/L

0.01667

1.67 μkat/L

Lithium, therapeutic

0.5–1.25 mEq/L

1

0.5–1.25 mmol/L

Low-density lipoprotein (LDL) cholesterol

 Target for very high-risk patients

< 70 mg/dL

0.0259

< 1.81 mmol/L

 Desirable LDL level and target for high-risk patients (optimal)

< 100 mg/dL

0.0259

< 2.59 mmol/L

 Above desirable

100-129 mg/dL

0.0259

2.59-3.34 mmol/L

 Borderline high risk

130–159 mg/dL

0.0259

3.36–4.11 mmol/L

 High risk

160-189 mg/dL

0.0259

4.14-4.89 mmol/L

 Very high risk

≥ 190 mg/dL

0.0259

≥ 4.91 mmol/L

Luteinizing hormone (LH)

 Male

1–8 mIU/mL

1

1–8 IU/L

 Female

  Follicular phase

1–12 mIU/mL

1

1–12 IU/L

  Midcycle

16–104 mIU/mL

1

16–104 IU/L

  Luteal phase

1–12 mIU/mL

1

1–12 IU/L

  Postmenopausal

16–66 mIU/mL

1

16–66 IU/L

Lymphocyte count

1.2–3.3 × 10³/mm³

10⁶

1.2–3.3 × 10⁹/L

Magnesium

1.3–2.2 mEq/L

1.58–2.68 mg/dL

0.5

0.411

0.65–1.10 mmol/L

0.65–1.10 mmol/L

Mean corpuscular volume (MCV)

80.0–97.6 μm³

1

80.0–97.6 fL

Mononuclear cell count

0.2–0.7 × 10³/mm³

10⁶

0.2–0.7 × 10⁹/L

Nortriptyline, therapeutic

50–150 ng/mL or mcg/L

3.797

190–570 nmol/L

Osmolality (serum)

275–300 mOsm/kg

1

275–300 mmol/kg

Osmolality (urine)

250–900 mOsm/kg

1

250–900 mmol/kg

Parathyroid hormone (PTH), intact

10–60 pg/mL or ng/L

0.107

1.1–6.4 pmol/L

PTH, N-terminal

8–24 pg/mL or ng/L

PTH, C-terminal

50–330 pg/mL or ng/L

Phenobarbital, therapeutic

15–40 mcg/mL or mg/L

4.31

65–172 μmol/L

Phenytoin, therapeutic (total concentration)

10–20 mcg/mL or mg/L

3.96

40–79 μmol/L

Phosphate

2.5–4.5 mg/dL

0.323

0.81–1.45 mmol/L

Platelet count

140–440 × 10³/mm³

10⁶

140–440 × 10⁹/L

Potassium (plasma)

3.3–4.9 mEq/L

1

3.3–4.9 mmol/L

Prealbumin (adult)

19.5–35.8 mg/dL

10

195–358 mg/L

Primidone, therapeutic

5–12 mcg/mL or mg/L

4.58

23–55 μmol/L

Procainamide, therapeutic

4–10 mcg/mL or mg/L

4.25

17–42 μmol/L

Progesterone

 Male

13–97 ng/dL

0.0318

0.4–3.1 nmol/L

 Female

  Follicular phase

15–70 ng/dL

0.0318

0.5–2.2 nmol/L

  Luteal phase

200–2500 ng/dL

0.0318

6.4–79.5 nmol/L

Prolactin

< 20 ng/mL

1

43.5

< 20 mcg/L

< 870 pmol/L

Prostate-specific antigen (PSA)

< 4 ng/mL

1

< 4 mcg/L

Protein, total

6.0–8.0 g/dL

10

60–80 g/L

Prothrombin time (PT)

10–12 seconds

Quinidine, therapeutic

2–5 mcg/mL or mg/L

3.08

6.2–15.4 μmol/L

Radioactive iodine uptake (RAIU)

< 6% in 2 hours

Red blood cell (RBC) count (blood)

 Male

4–6.2 × 10⁶/mm³

10⁶

4–6.2 × 10¹²/L

 Female

4–6.2 × 10⁶/mm³

10⁶

4–6.2 × 10¹²/L

  Pregnant

   Trimester 1

4–5 × 10⁶/mm³

10⁶

4–5 × 10¹²/L

   Trimester 2

3.2–4.5 × 10⁶/mm³

10⁶

3.2–4.5 × 10¹²/L

   Trimester 3

3–4.9 × 10⁶/mm³

10⁶

3–4.9 × 10¹²/L

  Postpartum

3.2–5 × 10⁶/mm³

10⁶

3.2–5 × 10¹²/L

Red blood cell distribution width (RDW)

11.5%–14.5%

0.01

0.115–0.145

Reticulocyte count

 Male

0.5%–1.5% of total RBC count

0.01

0.005–0.015

 Female

0.5%–2.5% of total RBC count

0.01

0.005–0.025

Retinol-binding protein (RBP)

2.7–7.6 mg/dL

10

27–76 mg/L

Rheumatoid factor (RF) titer

Negative

Salicylate, therapeutic

150–300 mcg/mL or mg/L

15–30 mg/dL

0.00724

0.0724

1.09–2.17 mmol/L

1.09–2.17 mmol/L

Sirolimus (renal transplant)

4–20 ng/mL

1

1.094

4–20 mcg/L

4–22 nmol/L

Sodium

135–145 mEq/L

1

135–145 mmol/L

Tacrolimus

 Renal, cardiac, liver, or pancreatic transplant

5–20 ng/mL

1

1.24

5–20 mcg/L

6.2-24.8 nmol/L

Testosterone (total)

 Men

300–950 ng/dL

0.0347

10.4–33.0 nmol/L

 Women

20–80 ng/dL

0.0347

0.7–2.8 nmol/L

Testosterone (free)

 Men

9–30 ng/dL

0.0347

0.31–1.04 nmol/L

 Women

0.3–1.9 ng/dL

0.0347

0.01–0.07 nmol/L

Theophylline

 Therapeutic

5–15 mcg/mL or mg/L

5.55

28–83 μmol/L

 Toxic

20 mcg/mL or mg/L or more

5.55

111 μmol/L or more

Thiocyanate

Toxic level unclear; units are mcg/mL or mg/L

17.2

μmol/L

Thrombin time

20–24 seconds

Thyroglobulin

< 42 ng/mL

1

< 42 mcg/L

Thyroglobulin antibodies

Negative

Thyroxine-binding globulin (TBG)

1.2–2.5 mg/dL

10

12–25 mcg/L

Thyroid-stimulating hormone (TSH)

0.35–6.20 μIU/mL

1

0.35–6.20 mIU/L

TSH receptor antibodies (TSHRab)

0–1 units/mL

0-1 kU/L

Thyroxine (T₄)

 Total

4.5–12.0 mcg/dL

12.87

58–154 nmol/L

 Free

0.7–1.9 ng/dL

12.87

9.0–24.5 pmol/L

Thyroxine index, free (FT₄I)

6.5–12.5

TIBC—see Iron binding capacity (total)

Tobramycin, therapeutic

 Peak

4–10 mcg/mL or mg/L

2.14

8.6–21.4 μmol/L

 Trough

≤ 2 mcg/mL or mg/L

2.14

≤ 4.3 μmol/L

Transferrin

200–430 mg/dL

0.01

2.0–4.3 g/L

Transferrin saturation

30–50%

0.01

0.30–0.50

Triglycerides (fasting)

< 160 mg/dL

0.0113

< 1.81 mmol/L

Triiodothyronine (T₃)

45–132 ng/dL

0.0154

0.69–2.03 nmol/L

Triiodothyronine (T₃) resin uptake

25–35%

Uric acid

3–8 mg/dL

59.48

178–476 μmol/L

Urinalysis (urine)

 pH

4.8–8.0

 Specific gravity

1.005–1.030

 Protein

Negative

 Glucose

Negative

 Ketones

Negative

 RBC

1–2 per low-power field

 WBC

< 5 per low-power field

Valproic acid, therapeutic

50–100 mcg/mL or mg/L

6.93

346–693 μmol/L

Vancomycin, therapeutic

 Peak

20–40 mcg/mL or mg/L

0.690

14–28 μmol/L

 Trough

10–20 mcg/mL or mg/L

0.690

7–14 μmol/L

 Trough for central nervous system infections

15–20 mcg/mL or mg/L

0.690

10–14 μmol/L

Vitamin A (retinol)

30–95 mcg/dL

0.0349

1.05–3.32 μmol/L

Vitamin B₁₂

180–1000 pg/mL

0.738

133–738 pmol/L

Vitamin D₃, 1,25-dihydroxy

20–76 pg/mL

2.4

48–182 pmol/L

Vitamin D₃, 25-hydroxy

10–50 ng/mL

2.496

25–125 nmol/L

Vitamin E (a-tocopherol)

0.5–2.0 mg/dL

23.22

12–46 μmol/L

WBC count

4–10 × 10³/mm³

10⁶

4–10 × 10⁹/L

WBC differential (peripheral blood)

 Polymorphonuclear neutrophils (PMNs)

50%–65%

0.01

0.50–0.65

 Bands

0%–5%

0.01

0–0.05

 Eosinophils

0%–3%

0.01

0–0.03

 Basophils

1%–3%

0.01

0.01–0.03

 Lymphocytes

25%–35%

0.01

0.25–0.35

 Monocytes

2%–6%

0.01

0.02–0.06

WBC differential (bone marrow)

 PMNs

3%–11%

0.01

0.03–0.11

 Bands

9%–15%

0.01

0.09–0.15

 Metamyelocytes

9%–25%

0.01

0.09–0.25

 Myelocytes

8%–16%

0.01

0.08–0.16

 Promyelocytes

1%–8%

0.01

0.01–0.08

 Myeloblasts

0%–5%

0.01

0–0.05

 Eosinophils

1%–5%

0.01

0.01–0.05

 Basophils

0%–1%

0.01

0–0.01

 Lymphocytes

11%–23%

0.01

0.11–0.23

 Monocytes

0%–1%

0.01

0–0.01

Zinc

60–150 mcg/dL

0.153

9.2–23.0 μmol/L